A retrospective study of 69 patients with t(6;9)(p23;q34) AML emphasizes the need for a prospective, multicenter initiative for rare 'poor prognosis' myeloid malignancies

¹The First Department of Internal Medicine (Hematology Division), Tokyo Medical University, Tokyo, Japan and ²Intractable Immune System Disease Research Center, Tokyo Medical University, Tokyo, Japan; E-mail: [email protected]